3,4-Dihydroxy-5-Nitrobenzaldehyde

3,4-Dihydroxy-5-Nitrobenzaldehyde

SCHEMBL346035

O=Cc1cc(O)c(O)c([N+](=O)[O-])c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 1.00
ALDH5A1 P51649 1/20 0.62
ABAT P80404 1/20 0.62
MEN1 O00255 2/20 0.61
ALDH1A1 P00352 2/20 0.61
MAPT P10636 2/20 0.61
HPGD P15428 2/20 0.61
RECQL P46063 2/20 0.61
KMT2A Q03164 2/20 0.61
GPR35 Q9HC97 2/20 0.61
KDM4E B2RXH2 1/20 0.58
TTR P02766 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
ALOX15 P16050 1/20 0.58
ALOX12 P18054 1/20 0.58
MAPK1 P28482 1/20 0.58
PMP22 Q01453 1/20 0.58
HIF1A Q16665 1/20 0.58
HSD17B10 Q99714 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL29357099 1.00 XDH (1.00) XDHALDH5A1ABATMEN1ALDH1A1
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL8731720 0.98 XDH (0.96) XDHALDH5A1ABATMEN1ALDH1A1
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL28213417 0.96 XDH (0.93) XDHALDH5A1ABATMEN1ALDH1A1
SCHEMBL6897071 0.90 XDH (0.81) XDHALDH5A1ABATMEN1ALDH1A1
SCHEMBL532580 0.85 XDH (0.74) XDHALDH5A1ABATMEN1ALDH1A1
SCHEMBL15783651 0.83 XDH (0.71) XDHALDH5A1ABAT
SCHEMBL16838205 0.83 XDH (0.71) XDHALDH5A1ABATMEN1ALDH1A1
SCHEMBL14492368 0.82 XDH (0.70) XDHALDH5A1ABATMEN1ALDH1A1
SCHEMBL7243507 0.82 XDH (0.70) XDHALDH5A1ABATMEN1ALDH1A1
SCHEMBL531545 0.81 XDH (0.69) XDHALDH5A1ABATMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016743-A1 A METHOD FOR PRODUCING ENTACAPONE TABLETS CHINA MEHECO KANGLI PHARMA CO., LTD. (CN) 2024-01-18 US claimed
US-20230346765-A1 METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-11-02 US claimed
CN-113109465-B Quality detection method and application of entacapone 海南通用康力制药有限公司 2023-04-07 CN claimed
EP-4121052-A1 METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF Baylor College of Medicine (US) 2023-01-25 EP claimed
CN-109336800-B DHNB (dehydroepiandrosterone) condensed phenylthiosemicarbazide compound as well as preparation method and application thereof 江西中医药大学 2022-11-29 CN claimed
WO-2022205574-A1 METHOD FOR PRODUCING ENTACAPONE TABLETS 海南通用康力制药有限公司 2022-10-06 WO claimed
CN-113481725-A Preparation method of medical antibacterial non-woven fabric 上海蟠龙医用材料有限公司 2021-10-08 CN claimed
CN-112680877-B Antibacterial non-woven fabric and preparation process thereof 浙江雅宝无纺布制品有限公司 2021-10-01 CN claimed
WO-2021188296-A1 METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2021-09-23 WO claimed
CN-109875988-B Synthesis of compound DHNB semicarbazone and application of compound DHNB semicarbazone in preventing and treating gout and hyperuricemia 江西中医药大学 2021-08-27 CN claimed
EP-0782559-A1 NEW METHOD FOR THE PREPARATION OF 3,4-DIHYDROXY-5-NITROBENZALDEHYDE ORIONYHTYMÄ OY (FI) 1997-07-09 EP claimed
EP-0444899-B1 Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation ORION YHTYMAE OY (FI) 1997-02-05 EP claimed
EP-0589948-B1 METHOD FOR THE PREPARATION OF 3,4-DIHYDROXY-5-NITROBENZALDEHYDE ORION YHTYMAE OY (FI) 1996-09-04 EP claimed
WO-1996009274-A1 NEW METHOD FOR THE PREPARATION OF 3,4-DIHYDROXY-5-NITROBENZALDEHYDE Orion-Yhtymä Oy (FI) 1996-03-28 WO claimed
US-5382699-A Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde ORION-YHTYMA OY (FI) 1995-01-17 US claimed
EP-0589948-A1 METHOD FOR THE PREPARATION OF 3,4-DIHYDROXY-5-NITROBENZALDEHYDE. ORION YHTYMAE OY (FI) 1994-04-06 EP claimed
EP-0323162-B1 NEW USE OF CATECHOL-O-METHYL TRANSFERASE (COMT) INHIBITORS AND THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS AND ESTERS ORION YHTYMAE OY (FI) 1993-09-15 EP claimed
WO-1993000323-A1 METHOD FOR THE PREPARATION OF 3,4-DIHYDROXY-5-NITROBENZALDEHYDE Orion-Yhtymä Oy (FI) 1993-01-07 WO claimed
EP-0444899-A2 Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation ORION-YHTYMÀ„ OY (FI) 1991-09-04 EP claimed
EP-0323162-A2 New use of catechol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters ORION-YHTYMÀ„ OY (FI) 1989-07-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346765-A1 METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF XDH, PNPO, PNP XDH 1/4885ALDH5A1 51/4885ABAT 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.